Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.17352/2455-8591.000024
Abstract: Doxorubicin, a WHO listed essential medicine, is used primarily as a combination of taxane/ anthracycline (doxorubicin)/cyclophosphamide (TAC), for treating malignant diseases including triple-negative breast cancer (TNBC). TNBC is a subtype of breast cancer categorized by… read more here.
Keywords: treat; immunotherapy; insights use; tnbc ... See more keywords